SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Corteva, Inc., et al. – ‘10-K’ for 12/31/19 – ‘R11’

On:  Friday, 2/14/20, at 7:29am ET   ·   For:  12/31/19   ·   Accession #:  1755672-20-6   ·   File #s:  1-00815, 1-38710

Previous ‘10-K’:  None   ·   Next:  ‘10-K’ on 2/11/21 for 12/31/20   ·   Latest:  ‘10-K’ on 2/8/24 for 12/31/23   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/14/20  Corteva, Inc.                     10-K       12/31/19  199:36M
          Dupont E I De Nemours & Co

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   4.78M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     67K 
 3: EX-4.2      Instrument Defining the Rights of Security Holders  HTML     60K 
 4: EX-21       Subsidiaries List                                   HTML    135K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     53K 
 6: EX-23.2     Consent of Experts or Counsel                       HTML     53K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     67K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     68K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     57K 
10: EX-32.2     Certification -- §906 - SOA'02                      HTML     57K 
90: R1          DEI Document                                        HTML    139K 
164: R2          Consolidated Statements of Income                   HTML    154K  
132: R3          Consolidated Statements of Comprehensive Income     HTML     90K  
28: R4          Consolidated Balance Sheets                         HTML    202K 
87: R5          Consolidated Balance Sheets (Parentheticals)        HTML     74K 
161: R6          Consolidated Statements of Cash Flows               HTML    254K  
130: R7          Consolidated Statements of Equity                   HTML    162K  
24: R8          Consolidated Statements of Equity (Parentheticals)  HTML     60K 
93: R9          Schedule II - Valuation and Qualifying Accounts     HTML     94K 
                (Notes)                                                          
179: R10         Background and Basis of Presentation (Notes)        HTML     83K  
153: R11         Summary of Significant Accounting Policies          HTML    113K  
34: R12         Recent Accounting Guidance                          HTML     92K 
101: R13         Business Combinations                               HTML     98K  
176: R14         Divestitures and Other Transactions                 HTML    247K  
150: R15         Revenue (Notes)                                     HTML    140K  
31: R16         Restructuring and Asset Related Charges             HTML    130K 
98: R17         Related Parties (Notes)                             HTML     60K 
175: R18         Supplementary Information                           HTML    138K  
154: R19         Income Taxes                                        HTML    243K  
47: R20         Earnings Per Share of Common Stock (Notes)          HTML    119K 
69: R21         Accounts and Notes Receivable, Net                  HTML     71K 
183: R22         Inventories                                         HTML     62K  
113: R23         Property, Plant and Equipment                       HTML     74K  
44: R24         Goodwill and Other Intangible Assets                HTML    167K 
66: R25         Leases (Notes)                                      HTML    112K 
180: R26         Short-Term Borrowings, Long-Term Debt and           HTML    134K  
                Available Credit Facilities                                      
110: R27         Commitments and Contingent Liabilities              HTML    117K  
48: R28         Stockholders' Equity                                HTML    236K 
65: R29         Pension Plans and Other Post Employment Benefit     HTML    561K 
                Plans                                                            
103: R30         Stock-Based Compensation                            HTML    196K  
36: R31         Financial Instruments                               HTML    174K 
145: R32         Fair Value Measurements                             HTML     99K  
171: R33         Geographic Information                              HTML     88K  
106: R34         Segment Reporting (Notes)                           HTML    191K  
39: R35         Quaterly Financial Data                             HTML    189K 
148: R36         Subsequent Events (Notes)                           HTML     55K  
174: R37         EID Basis of Presentation (Notes)                   HTML    105K  
107: R38         EID Related Party (Notes)                           HTML     65K  
35: R39         EID Income Taxes (Notes)                            HTML    327K 
71: R40         EID Segment FN (Notes)                              HTML    217K 
51: R41         EID Quarterly FN (Notes)                            HTML    233K 
126: R42         Background and Basis of Presentation (Policies)     HTML     95K  
197: R43         Summary of Significant Accounting Policies          HTML    198K  
                (Policies)                                                       
72: R44         Recent Accounting Guidance Recent Accounting        HTML     91K 
                Guidance (Policies)                                              
53: R45         Recent Accounting Guidance Accounting               HTML     83K 
                Pronouncements (Tables)                                          
127: R46         Business Combinations (Tables)                      HTML     98K  
198: R47         Divestitures and Other Transactions (Tables)        HTML    237K  
74: R48         Revenue (Tables)                                    HTML    133K 
49: R49         Restructuring and Asset Related Charges (Tables)    HTML    125K 
18: R50         Supplementary Information (Tables)                  HTML    138K 
85: R51         Income Taxes (Tables)                               HTML    244K 
167: R52         Earnings Per Share of Common Stock (Tables)         HTML    129K  
143: R53         Accounts and Notes Receivable, Net (Tables)         HTML     65K  
17: R54         Inventories (Tables)                                HTML     62K 
84: R55         Property, Plant and Equipment (Tables)              HTML     75K 
166: R56         Goodwill and Other Intangible Assets (Tables)       HTML    154K  
142: R57         Leases (Tables)                                     HTML    115K  
20: R58         Short-Term Borrowings, Long-Term Debt and           HTML    127K 
                Available Credit Facilities (Tables)                             
82: R59         Commitments and Contingent Liabilities (Tables)     HTML     75K 
192: R60         Stockholders' Equity (Tables)                       HTML    243K  
120: R61         Pension Plans and Other Post Employment Benefit     HTML    545K  
                Plans (Tables)                                                   
59: R62         Stock-Based Compensation (Tables)                   HTML    173K 
78: R63         Financial Instruments (Tables)                      HTML    170K 
191: R64         Fair Value Measurements (Tables)                    HTML     95K  
119: R65         Geographic Information (Tables)                     HTML     91K  
58: R66         Segment Reporting (Tables)                          HTML    196K 
77: R67         Quaterly Financial Data (Tables)                    HTML    186K 
187: R68         EID Income Taxes (Tables)                           HTML    223K  
123: R69         EID Segment FN (Tables)                             HTML    101K  
136: R70         EID Quarterly FN (Tables)                           HTML    230K  
157: R71         Schedule II - Valuation and Qualifying Accounts     HTML     78K  
                (Details)                                                        
94: R72         Background and Basis of Presentation (Details)      HTML     79K 
23: R73         Summary of Significant Accounting Policies          HTML     81K 
                (Details)                                                        
137: R74         Recent Accounting Guidance Lease ASU - Effect on    HTML     95K  
                Balance Sheet (Details)                                          
158: R75         Business Combinations DAS Common Control Transfer   HTML    120K  
                - Balance Sheet (Details)                                        
95: R76         Business Combinations DAS Common Control Transfer   HTML     98K 
                Income Statement (Details)                                       
25: R77         Divestitures and Other Transactions Divestitures    HTML    115K 
                and Other Transactions - Narrative (Details)                     
133: R78         Divestitures and Other Transactions ECP             HTML    199K  
                Divestiture (Details)                                            
163: R79         Divestitures and Other Transactions SP Divestiture  HTML    229K  
                (Details)                                                        
135: R80         Divestitures and Other Transactions Divestitures    HTML    110K  
                and Other Transactions - Divested Ag Business                    
                Results of Operations (Details)                                  
156: R81         Divestitures and Other Transactions Divestitures    HTML     58K  
                and Other Transactions - Divested Ag Business                    
                Depreciation and Capital Expenditures (Details)                  
91: R82         Divestitures and Other Transactions Divestitures    HTML     95K 
                and Other Transactions - PChem Results of                        
                Operations (Details)                                             
21: R83         Revenue Narrative (Details)                         HTML     60K 
139: R84         Revenue Contract Balances (Details)                 HTML     70K  
160: R85         Revenue Disaggregation of Revenue - Products        HTML     88K  
                (Details)                                                        
96: R86         Revenue Disaggregation of Revenue - Geo (Details)   HTML    101K 
26: R87         Restructuring and Asset Related Charges DowDuPont   HTML    106K 
                Agriculture Division Restructuring Program                       
                (Details)                                                        
131: R88         Restructuring and Asset Related Charges DowDuPont   HTML    111K  
                Cost Synergy Program (Details)                                   
162: R89         Restructuring and Asset Related Charges Asset       HTML     62K  
                Impairments (Details)                                            
193: R90         Related Parties Services Provided by and to Dow     HTML     61K  
                (Details)                                                        
121: R91         Related Parties Transactions with DowDuPont         HTML     64K  
                (Details)                                                        
61: R92         Supplementary Information Other Income (Expense) -  HTML    116K 
                Net (Details)                                                    
80: R93         Supplementary Information Foreign Currency          HTML     81K 
                Exchange Gain (Loss) (Details)                                   
189: R94         Supplementary Information Reconciliation of Cash,   HTML     78K  
                Cash Equivalents and Restricted Cash (Details)                   
117: R95         Supplementary Information Supplementary             HTML     58K  
                Information (Narrative) (Details)                                
57: R96         Income Taxes Income Taxes - Narrative (Details)     HTML     66K 
76: R97         Income Taxes Income Taxes - Geographic Allocation   HTML     99K 
                of Income and Provision for Income Taxes (Details)               
188: R98         Income Taxes Income Taxes - Reconciliation to US    HTML    127K  
                Statutory Rate (Details)                                         
124: R99         Income Taxes Income Taxes - Deferred Tax Balances   HTML    110K  
                (Details)                                                        
196: R100        Income Taxes Income Taxes - Operating Loss and Tax  HTML     65K  
                Credit Carryforwards (Details)                                   
125: R101        Income Taxes Income Taxes - Gross Unrecognized Tax  HTML     83K  
                Benefits (Details)                                               
50: R102        Earnings Per Share of Common Stock Net Income for   HTML     91K 
                EPS Calc Basic and Diluted (Details)                             
70: R103        Earnings Per Share of Common Stock EPS Calculation  HTML     67K 
                - Basic (Details)                                                
199: R104        Earnings Per Share of Common Stock EPS Calculation  HTML     68K  
                - Diluted (Details)                                              
128: R105        Earnings Per Share of Common Stock Share Count      HTML     80K  
                Information (Details)                                            
54: R106        Accounts and Notes Receivable, Net (Schedule of     HTML     76K 
                Accounts and Notes Receivable, Net) (Details)                    
73: R107        Accounts and Notes Receivable, Net Customer         HTML     60K 
                Financing (Details)                                              
195: R108        Inventories Schedule of Inventory (Details)         HTML     72K  
129: R109        Property, Plant and Equipment Schedule of           HTML     89K  
                Property, Plant and Equipment (Details)                          
144: R110        Property, Plant and Equipment Schedule of           HTML     55K  
                Depreciation (Details)                                           
168: R111        Goodwill and Other Intangible Assets Goodwill by    HTML    108K  
                Segment (Details)                                                
86: R112        Goodwill and Other Intangible Assets Other          HTML    107K 
                Intangible Assets (Details)                                      
19: R113        Goodwill and Other Intangible Assets Amortization   HTML     74K 
                Expense (Details)                                                
141: R114        Leases Narrative (Details)                          HTML     62K  
165: R115        Leases Lease Costs (Details)                        HTML     68K  
83: R116        Leases Supplemental Cash Flow Information           HTML     58K 
                (Details)                                                        
16: R117        Leases Supplemental Balance Sheet Information       HTML     81K 
                (Details)                                                        
140: R118        Leases Lease Term and Discount Rate (Details)       HTML     61K  
169: R119        Leases Maturity of Lease Liabilities (Details)      HTML     90K  
79: R120        Leases Future Minimum Lease Commitments (Details)   HTML     73K 
60: R121        Short-Term Borrowings, Long-Term Debt and           HTML     70K 
                Available Credit Facilities Short-Term Borrowings                
                and Capital Lease Obligations (Details)                          
122: R122        Short-Term Borrowings, Long-Term Debt and           HTML     99K  
                Available Credit Facilities Long Term Debt                       
                (Details)                                                        
194: R123        Short-Term Borrowings, Long-Term Debt and           HTML     77K  
                Available Credit Facilities Available Committed                  
                Credit Facilities (Narrative) (Details)                          
75: R124        Short-Term Borrowings, Long-Term Debt and           HTML    148K 
                Available Credit Facilities Debt                                 
                Redemptions/Repayments (Details)                                 
56: R125        Short-Term Borrowings, Long-Term Debt and           HTML     55K 
                Available Credit Facilities Uncommitted Credit                   
                Facilities and Outstanding Letters of Credit                     
                (Details)                                                        
118: R126        Commitments and Contingent Liabilities Guarantee    HTML     61K  
                Narrative (Details)                                              
190: R127        Commitments and Contingent Liabilities Litigation   HTML     65K  
                - Chemours (Details)                                             
81: R128        Commitments and Contingent Liabilities Litigation   HTML     71K 
                - DuPont (Details)                                               
55: R129        Commitments and Contingent Liabilities Litigation   HTML     96K 
                - Leach and MDL Settlement (Details)                             
22: R130        Commitments and Contingent Liabilities Litigation   HTML     56K 
                - Fayetteville (Details)                                         
92: R131        Commitments and Contingent Liabilities              HTML     86K 
                Environmental (Details)                                          
155: R132        Stockholders' Equity Common Stock (Details)         HTML     89K  
134: R133        Stockholders' Equity Noncontrolling Interest        HTML     68K  
                (Details)                                                        
27: R134        Stockholders' Equity Other Comprehensive Income     HTML    123K 
                (Loss) (Details)                                                 
97: R135        Stockholders' Equity Tax Benefit (Expense) on Net   HTML     63K 
                Activity (Details)                                               
159: R136        Stockholders' Equity Reclassifications out of AOCI  HTML    152K  
                (Details)                                                        
138: R137        Pension Plans and Other Post Employment Benefit     HTML    121K  
                Plans Additional Information (Details)                           
29: R138        Pension Plans and Other Post Employment Benefit     HTML     58K 
                Plans Weighted Average Assumptions used to                       
                Determine Benefit Obligations - Pension (Details)                
88: R139        Pension Plans and Other Post Employment Benefit     HTML     67K 
                Plans Weighted Average Assumptions used to                       
                Determine Net Periodic Benefit Cost - Pension                    
                (Details)                                                        
40: R140        Pension Plans and Other Post Employment Benefit     HTML     59K 
                Plans Weighted Average Assumptions used to                       
                Determine Benefit Obligations and Periodic Benefit               
                Cost - OPEB (Details)                                            
63: R141        Pension Plans and Other Post Employment Benefit     HTML     61K 
                Plans Assumed Health Care Cost Trend Rates                       
                (Details)                                                        
185: R142        Pension Plans and Other Post Employment Benefit     HTML    153K  
                Plans Change in Projected Benefit Obligations,                   
                Plan Assets and Funded Status (Details)                          
115: R143        Pension Plans and Other Post Employment Benefit     HTML    109K  
                Plans Amounts Recognized in Consolidated Balance                 
                Sheets (Details)                                                 
41: R144        Pension Plans and Other Post Employment Benefit     HTML     62K 
                Plans Pension Plans with Projected Benefit                       
                Obligations in Excess of Plan Assets (Details)                   
64: R145        Pension Plans and Other Post Employment Benefit     HTML     64K 
                Plans Pension Plans with Accumulated Benefit                     
                Obligations in Excess of Plan Assets (Details)                   
186: R146        Pension Plans and Other Post Employment Benefit     HTML    130K  
                Plans Components of net periodic benefit cost                    
                (Credit) and Amounts Recognized in Other                         
                Comprehensive Loss (Details)                                     
116: R147        Pension Plans and Other Post Employment Benefit     HTML     73K  
                Plans Estimated Future Benefit Payments (Details)                
43: R148        Pension Plans and Other Post Employment Benefit     HTML     71K 
                Plans Target Allocation for Plan Assets (Details)                
62: R149        Pension Plans and Other Post Employment Benefit     HTML    186K 
                Plans Basis of Fair Value Measurement (Details)                  
100: R150        Pension Plans and Other Post Employment Benefit     HTML    130K  
                Plans Summary of Fair Value Measurement of Level 3               
                Pension Plan Assets (Details)                                    
33: R151        Stock-Based Compensation Stock Compensation         HTML     81K 
                (Details)                                                        
152: R152        Stock-Based Compensation Weighted Average           HTML     65K  
                Assumptions - Stock Options (Details)                            
178: R153        Stock-Based Compensation Stock Options (Details)    HTML    163K  
99: R154        Stock-Based Compensation Restricted Stock Units     HTML    179K 
                and Performance Deferred Stock (Details)                         
32: R155        Financial Instruments Financial Instruments         HTML     58K 
                (Narrative) (Details)                                            
151: R156        Financial Instruments Notional Amounts (Details)    HTML     61K  
177: R157        Financial Instruments Cash Flow Hedges Included in  HTML     71K  
                AOCI (Details)                                                   
102: R158        Financial Instruments Fair Value of Derivatives     HTML     81K  
                (Details)                                                        
30: R159        Financial Instruments Effect of Derivative          HTML     82K 
                Instruments (Details)                                            
112: R160        Fair Value Measurements Fair Value Measurement      HTML     77K  
                Recurring Basis (Details)                                        
182: R161        Fair Value Measurements Fair Value Measurement      HTML     83K  
                Nonrecurring Basis (Details)                                     
68: R162        Geographic Information Revenue by Country           HTML     83K 
                (Details)                                                        
46: R163        Geographic Information Net Property by Country      HTML     68K 
                (Details)                                                        
111: R164        Segment Reporting Segment Information (Details)     HTML    106K  
181: R165        Segment Reporting Segment Reconciliation (Details)  HTML    142K  
67: R166        Segment Reporting Segment Assets (Details)          HTML     63K 
45: R167        Segment Reporting Other Items (Details)             HTML     67K 
108: R168        Segment Reporting Sig Items (Details)               HTML    182K  
184: R169        Quaterly Financial Data Quarterly Financial Data    HTML    106K  
                (Details)                                                        
172: R170        Quaterly Financial Data Quarterly Financial Data    HTML    112K  
                (Parentheticals) (Details)                                       
146: R171        Quaterly Financial Data Quarterly Financial Data    HTML    115K  
                Restatement (Details)                                            
37: R172        Subsequent Events (Details)                         HTML     59K 
104: R173        EID Basis of Presentation (Details)                 HTML     57K  
173: R174        EID Related Party (Details)                         HTML     66K  
147: R175        EID Income Taxes Geographic Allocation (Details)    HTML    108K  
38: R176        EID Income Taxes Rate Reconciliation (Details)      HTML    154K 
105: R177        EID Segment FN Segment Reconciliation (Details)     HTML    172K  
170: R178        EID Quarterly FN (Details)                          HTML     77K  
149: R179        EID Quarterly FN Reconciliations (Details)          HTML    101K  
109: XML         IDEA XML File -- Filing Summary                      XML    384K  
42: XML         XBRL Instance -- ctva-12x31x201910xk_htm             XML  11.47M 
89: EXCEL       IDEA Workbook of Financial Reports                  XLSX    310K 
12: EX-101.CAL  XBRL Calculations -- dd-20191231_cal                 XML    299K 
13: EX-101.DEF  XBRL Definitions -- dd-20191231_def                  XML   2.96M 
14: EX-101.LAB  XBRL Labels -- dd-20191231_lab                       XML   3.90M 
15: EX-101.PRE  XBRL Presentations -- dd-20191231_pre                XML   3.28M 
11: EX-101.SCH  XBRL Schema -- dd-20191231                           XSD    477K 
114: JSON        XBRL Instance as JSON Data -- MetaLinks              819±  1.29M  
52: ZIP         XBRL Zipped Folder -- 0001755672-20-000006-xbrl      Zip   1.14M 


‘R11’   —   Summary of Significant Accounting Policies


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.19.3.a.u2
Summary of Significant Accounting Policies
12 Months Ended
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Consolidated Financial Statements include the accounts of the company and subsidiaries in which a controlling interest is maintained. For those consolidated subsidiaries in which the company's ownership is less than 100 percent, the outside stockholders' interests are shown as noncontrolling interests. Investments in affiliates over which the company has the ability to exercise significant influence but does not have a controlling interest are accounted for under the equity method.

The company is also involved with certain joint ventures accounted for under the equity method of accounting that are variable interest entities ("VIEs"). The company is not the primary beneficiary, as the nature of the company's involvement with the VIEs does not provide it the power to direct the VIEs significant activities. Future events may require these VIEs to be consolidated if the company becomes the primary beneficiary. At December 31, 2019 and 2018, the maximum exposure to loss related to the nonconsolidated VIEs is not considered material to the Consolidated Financial Statements.

Use of Estimates in Financial Statement Preparation
The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The company’s consolidated financial statements include amounts that are based on management’s best estimates and judgments. Actual results could differ from those estimates.

Changes in Accounting and Reporting
Within the Successor periods, EID made the following changes in accounting and reporting to harmonize its accounting and reporting with DowDuPont.
Within the Successor periods of the Consolidated Statements of Operations:
Included royalty income within net sales. In the Predecessor period, royalty income is included within other income (expense) - net.
Eliminated the other operating charges line item. In the Successor periods, a majority of these costs are included within cost of goods sold. These costs are also included in selling, general and administrative expenses and amortization of intangibles in the Successor periods.
Presented amortization of intangibles as a separate line item. In the Predecessor period, amortization is included within cost of goods sold, selling, general and administrative expenses, other operating charges, and research and development expenses.
Presented integration and separation costs as a separate line item. In the Predecessor period, these costs totaled $354 million and are included within selling, general and administrative expenses.
Included interest accrued related to unrecognized tax benefits within the (benefit from) provision for income taxes on continuing operations. In the Predecessor period, interest accrued related to unrecognized tax benefits is included within other income (expense) - net.

Within the Successor periods of the Consolidated Statements of Cash Flows:
Included foreign currency exchange contract settlements within cash flows from operating activities, regardless of hedge accounting qualification. In the Predecessor period, EID reflected non-qualified hedge programs, specifically forward contracts, options and cash collateral activity, within cash flows from investing activities. In the Predecessor period, EID reflected cash flows from qualified programs within the line item it related to (i.e., revenue hedge cash flows presented within changes from accounts receivable).
Aligned the line items within "changes in assets and liabilities, net of effects of acquired and divested companies" to the DowDuPont presentation, including accounts and notes receivable, inventories, accounts payable, and other assets and liabilities. In the Predecessor period, the line item "changes in assets and liabilities, net of effects of acquired and divested companies" includes accounts and notes receivable, inventories and other operating assets, accounts payable and other operating liabilities, and accrued interest and income taxes.

Cash and Cash Equivalents
Cash equivalents represent investments with maturities of three months or less from time of purchase. They are carried at cost plus accrued interest.
 
Restricted Cash
Restricted cash represents trust assets of $409 million and $460 million as of December 31, 2019 and 2018, respectively, and is included within other current assets on the Consolidated Balance Sheets. See Note 9 - Supplementary Information, for further information.

Marketable Securities
Marketable securities represent investments in fixed and floating rate financial instruments with maturities greater than three months and up to twelve months at time of purchase. Investments classified as held-to-maturity are recorded at amortized cost. The carrying value approximates fair value due to the short-term nature of the investments. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss). The cost of investments sold is determined by specific identification.

Fair Value Measurements
Under the accounting guidance for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The company uses the following valuation techniques to measure fair value for its assets and liabilities:
Level 1
Quoted market prices in active markets for identical assets or liabilities;
 
 
 
Level 2
Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs);
 
 
 
Level 3
Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability.


Foreign Currency Translation
The company's worldwide operations utilize the U.S. dollar ("USD") or local currency as the functional currency, where applicable. The company identifies its separate and distinct foreign entities and groups the foreign entities into two categories: 1) extension of the parent or foreign subsidiaries operating in a hyper-inflationary environment (USD functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. 

For foreign entities where the USD is the functional currency, all foreign currency-denominated asset and liability amounts are re-measured into USD at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are re-measured at historical rates. Foreign currency income and expenses are re-measured at average exchange rates in effect during the year, except for expenses related to balance sheet amounts re-measured at historical exchange rates. Exchange gains and losses arising from re-measurement of foreign currency-denominated monetary assets and liabilities are included in income in the period in which they occur.

For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into USD at end-of-period exchange rates and the resultant translation adjustments are reported, net of their related tax effects, as a component of accumulated other comprehensive loss in equity. Assets and liabilities denominated in other than the local currency are re-measured into the local currency prior to translation into USD and the resultant exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into USD at average exchange rates in effect during the period.

The company changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed.

Inventories
The company's inventories are valued at the lower of cost or net realizable value. Elements of cost in inventories include raw materials, direct labor and manufacturing overhead. Stores and supplies are valued at cost or net realizable value, whichever is lower; cost is generally determined by the average cost method.

As of December 31, 2019, approximately 59% and 41% of the company's inventories were accounted for under the first-in, first-out ("FIFO") and average cost methods, respectively. As of December 31, 2018, approximately 57% and 43% of the company's inventories were accounted for under the FIFO and average cost methods, respectively. Inventories accounted for under the FIFO method are primarily comprised of products with shorter shelf lives such as seeds. See Note 13 - Inventories, for further information.

The company establishes allowances for obsolescence of inventory based upon quality considerations and assumptions about future demand and market conditions.

Property, Plant and Equipment
Property, plant and equipment are carried at cost less accumulated depreciation. In connection with the Merger, the fair value of property, plant and equipment was determined using a market approach and a replacement cost approach. Depreciation is based on the estimated service lives of depreciable assets and is calculated using the straight-line method. Fully depreciated assets are retained in property and accumulated depreciation accounts until they are removed from service. When assets are surrendered, retired, sold, or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the Consolidated Balance Sheets and included in determining gain or loss on such disposals.

Goodwill and Other Intangible Assets
The company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is tested for impairment at the reporting unit level annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. In connection with the Merger Transaction, the company adopted the policy of DowDuPont and performs an annual goodwill impairment test in the fourth quarter.

When testing goodwill for impairment, the company has the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value.  If the company chooses not to complete a qualitative assessment for a given reporting unit or if the initial assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, additional quantitative testing is required.  The company determined fair values for each of the reporting units using the income approach and the market approach. Under the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. Under the market approach, the company uses metrics of publicly traded companies or historically completed transactions for comparable companies. See Note 15 - Goodwill and Other Intangible Assets, for further information on goodwill.

Indefinite-lived intangible assets are tested for impairment at least annually; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Impairment exists when carrying value exceeds fair value. The company's fair value methodology is primarily based on discounted cash flow techniques.

Definite-lived intangible assets are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging primarily from 2 years to 25 years. The company continually evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the Consolidated Balance Sheets.

Leases
The company adopted ASU 2016-02, Leases (Topic 842), and associated ASUs related to Topic 842, in the first quarter of 2019. Prior periods are not restated and continue to be reported under ASC 840. Under Topic 842, the company determines whether an arrangement is a lease at the inception of the arrangement based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the company has the right to control the asset. Operating lease right-of-use ("ROU") assets are included in other assets on the company’s Consolidated Balance Sheets. Operating lease liabilities are included in accrued and other current liabilities and other noncurrent obligations on the company’s Consolidated Balance Sheets. Finance lease assets are included in property, plant and equipment on the company’s Consolidated Balance Sheets. Finance lease liabilities are included in short-term borrowings and finance lease obligations and long-term debt on the company’s Consolidated Balance Sheets.  

Operating lease ROU assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the company’s leases do not provide the lessor's implicit rate, the company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments. Lease terms include options to extend the lease when it is reasonably certain those options will be exercised. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The company recognizes lease expense for these leases on a straight-line basis over the lease term.

The company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. In the Consolidated Statements of Operations, lease expense for operating lease payments is recognized on a straight-line basis over the lease term. For finance leases, interest expense is recognized on the lease liability and the ROU asset is amortized over the lease term. See Note 16 - Leases, for further information.

Impairment of Long-Lived Assets
The company evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. The carrying value of a long-lived asset group is considered impaired when the total projected undiscounted cash flows from the assets are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The company's fair value methodology is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of by sale, if material, are classified as held for sale and reported at the lower of carrying amount or fair value less cost to sell, and depreciation is ceased. Long-lived assets to be disposed of other than by sale are classified as held and used until they are disposed of and reported at the lower of carrying amount or fair value. Depreciation is recognized over the remaining useful life of the assets.

Derivative Instruments
Derivative instruments are reported in the Consolidated Balance Sheets at their fair values. The company utilizes derivatives to manage exposures to foreign currency exchange rates and commodity prices. Changes in the fair values of derivative instruments that are not designated as hedges are recorded in current period earnings. For derivative instruments designated as cash flow hedges, the (loss) gain is reported in accumulated other comprehensive loss until it is cleared to earnings during the same period in which the hedged item affects earnings.

In the event that a derivative designated as a hedge of a firm commitment or an anticipated transaction is terminated prior to the maturation of the hedged transaction, the net gain or loss in accumulated other comprehensive income ("AOCI") generally remains in AOCI until the item that was hedged affects earnings. If a hedged transaction matures, or is sold, extinguished, or terminated prior to the maturity of a derivative designated as a hedge of such transaction, gains or losses associated with the derivative through the date the transaction matured are included in the measurement of the hedged transaction and the derivative is reclassified as for trading purposes. Derivatives designated as hedges of anticipated transactions are reclassified as for trading purposes if the anticipated transaction is no longer probable.

In the Predecessor period, the company reflected non-qualified hedge programs, specifically forward contracts, options and cash collateral activity, within cash flows from investing activities. In the Predecessor period, the company reflected cash flows from qualified programs within the line item it related to (i.e., revenue hedge cash flows presented within changes from accounts receivable). In the Successor periods, the company included foreign currency exchange contract settlements within cash flows from operating activities, regardless of hedge accounting qualification. See Note 22 - Financial Instruments, for additional discussion regarding the company's objectives and strategies for derivative instruments.

Environmental Matters
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Accruals for environmental liabilities are included in the Consolidated Balance Sheets in accrued and other current liabilities and other noncurrent obligations at undiscounted amounts. Accruals for related insurance or other third-party recoveries for environmental liabilities are recorded when it is probable that a recovery will be realized and are included in the Consolidated Balance Sheets as accounts and notes receivable - net.

Environmental costs are capitalized if the costs extend the life of the property, increase its capacity, and/or mitigate or prevent contamination from future operations. Environmental costs are also capitalized in recognition of legal asset retirement obligations resulting from the acquisition, construction and/or normal operation of a long-lived asset. Costs related to environmental contamination treatment and cleanup are charged to expense. Estimated future incremental operations, maintenance and management costs directly related to remediation are accrued when such costs are probable and reasonably estimable.

Revenue Recognition
The company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. To determine revenue recognition for the arrangements that the company determines are within the scope of FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), the company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. See Note 6 - Revenue, for additional information on revenue recognition.

Prepaid Royalties
The company currently has certain third-party biotechnology trait license agreements, which require up-front and variable payments subject to the licensor meeting certain conditions. These payments are reflected as other current assets and other assets and are amortized to cost of goods sold as seeds containing the respective trait technology are utilized over the life of the license. The rate of royalty amortization expense recognized is based on the company’s strategic plans which include various assumptions and estimates including product portfolio, market dynamics, farmer preferences, growth rates and projected planted acres. Changes in factors and assumptions included in the strategic plans, including potential changes to the product portfolio in favor of internally developed biotechnology, could impact the rate of recognition of the relevant prepaid royalty.

At December 31, 2019, the balance of prepaid royalties reflected in other current assets and other assets was $440 million and $794 million, respectively. The majority of the balance of prepaid royalties relates to the company’s wholly owned subsidiary, Pioneer Hi-Bred International, Inc.’s (“Pioneer”) non-exclusive license in the United States and Canada for the Monsanto Company's Genuity® Roundup Ready 2 Yield® glyphosate tolerance trait and Roundup Ready 2 Xtend® glyphosate and dicamba tolerance trait for soybeans (“Roundup Ready 2 License Agreement”). Each of these licensed technologies are now trademarks of the Bayer Group, which acquired the Monsanto Company in 2018. The prepaid royalty asset relates to a series of up-front, fixed and variable royalty payments to utilize the traits in Pioneer’s soybean product mix. The company’s historical expectation has been that the technology licensed under the Roundup Ready 2 License Agreement would be used as the primary herbicide tolerance trait platform in the Pioneer® brand soybean through the term of the agreement. DAS and MS Technologies, L.L.C. jointly developed and own the Enlist E3TM herbicide tolerance trait for soybeans which provides tolerance to 2, 4-D choline in Enlist Duo® and Enlist One® herbicides, as well as glyphosate and glufosinate herbicides. In connection with the validation of breeding plans and large-scale product development timelines, during the fourth quarter of 2019, the company is accelerating the ramp up of the Enlist E3TM trait platform in the company’s soybean portfolio mix across all brands, including Pioneer® brands, over the next five years. During the ramp-up period, the company is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter for the remainder of the Roundup Ready 2 License Agreement (the “Transition Plan”). The rate of royalty expense is therefore expected to significantly increase through higher amortization of the prepaid royalty as fewer seeds containing the respective trait are expected to be utilized.

In connection with the departure from these traits, beginning January 1, 2020 the company will present and disclose the non-cash accelerated prepaid royalty amortization expense as a component of Restructuring and Asset Related Charges - Net, in the Consolidated Statement of Operations. The accelerated prepaid royalty amortization expense will represent the difference between the rate of amortization based on the revised number of units expected to contain the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® trait technology and the variable cash rate per the Roundup Ready 2 License Agreement.

Further changes in factors and assumptions associated with usage of the trait platform licensed under the Roundup Ready 2 License Agreement, including the Transition Plan, could further impact the rate of recognition of the prepaid royalty and statement of operations presentation of the accelerated prepaid royalty amortization expense.

Cost of Goods Sold
Successor periods - Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages and benefits and overhead, non-capitalizable costs associated with capital projects, royalties and other operational expenses.  No amortization of intangibles is included within costs of goods sold.

Predecessor period - Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages and benefits, and overhead.

Other Operating Charges
Predecessor period - Other operating charges includes product claim charges and recoveries, non-capitalizable costs associated with capital projects, and other operational expenses. 

Research and Development
Research and development costs are expensed as incurred. Research and development expense includes costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products, and regulatory approval of new and existing products.

Selling, General and Administrative Expenses
Successor periods - Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs, and business management expenses.

Predecessor period - Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs, business management expenses, and integration and separation costs.

Integration and Separation Costs
Successor periods - Integration and separation costs includes costs incurred to prepare for and close the Merger, post-Merger integration expenses, and costs incurred to prepare for the Business Separations. These costs primarily consist of financial advisory, information technology, legal, accounting, consulting and other professional advisory fees associated with preparation and execution of these activities.

Litigation and Other Contingencies
Accruals for legal matters and other contingencies are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Legal costs, such as outside counsel fees and expenses, are charged to expense in the period incurred.

Severance Costs
Severance benefits are provided to employees under the company's ongoing benefit arrangements. Severance costs are accrued when management commits to a plan of termination and it becomes probable that employees will be entitled to benefits at amounts that can be reasonably estimated.

Insurance/Self-Insurance
The company self-insures certain risks where permitted by law or regulation, including workers' compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable.

Income Taxes
The company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities using enacted tax rates. The effect of a change in tax rates on deferred tax assets or liabilities is recognized in income in the period that includes the enactment date (see Note 10 - Income Taxes, for further information relating to the enactment of the Tax Cuts and Job Act).

The company recognizes the financial statement effects of an uncertain income tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The current portion of uncertain income tax positions is included in income taxes payable and the long-term portion is included in other noncurrent obligations in the Consolidated Balance Sheets.

Income tax related penalties are included in the provision for income taxes in the Consolidated Statements of Operations. Interest accrued related to unrecognized tax benefits is included within the (benefit from) provision for income taxes from continuing operations in the Consolidated Statements of Operations in the Successor periods. In the Predecessor period, interest accrued related to unrecognized tax benefits is included within other income (expense) - net in the Consolidated Statements of Operations.

Earnings per Common Share
The calculation of earnings per common share is based on the weighted-average number of the company’s common shares outstanding for the applicable period. The calculation of diluted earnings per common share reflects the effect of all potential common shares that were outstanding during the respective periods, unless the effect of doing so is antidilutive.

Segments
As a result of the Corteva Distribution, the company changed its reportable segments to seed and crop protection to reflect the manner in which the company's chief operating decision maker assesses performance and allocates resources.  The company also updated its reporting units to align with the level at which discrete financial information is available for review by management.

Prior year segment information has been revised to conform to the current presentation, excluding the Predecessor and Successor periods of 2017. See Note 25 - Segment Information, for further information.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/14/204,  POSASR,  SC 13G
1/1/20
For Period end:12/31/1911-K,  4
12/31/1810-K,  SD
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/08/24  Corteva, Inc.                     10-K       12/31/23  176:25M
 2/09/23  Corteva, Inc.                     10-K       12/31/22  166:28M
 2/10/22  Corteva, Inc.                     10-K       12/31/21  187:29M
 2/11/21  Corteva, Inc.                     10-K       12/31/20  196:32M
11/05/20  Corteva, Inc.                     S-8        11/05/20    6:168K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001755672-20-000006   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 7:06:28.2pm ET